EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease

Zewei Chen, Dechao Xu, Shuangcheng Wu, Wenyu Liu, Jianxiang Wu, Shengqiang Yu, Bing Dai, Zhiguo Mao, Xiang Gao

Clinical Kidney Journal · 04.03.2025 · 18 (3)

DOI: 10.1093/ckj/sfaf039 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 08.02.2025. Verfasst von Zewei Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Changzheng Hospital, Naval Medical University, Shanghai, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Research Project of Shanghai Municipal Health Commission, Oriental Talent Plan Outstanding Program 2023, the Shanghai Municipal Key Clinical Specialty.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obinutuzumab, a new-generation anti-CD20 monoclonal antibody, was originally developed to overcome resistance to rituximab in B-cell malignancies. There is limited research regarding the use of obinutuzumab in patients with rituximab-refractory membranous nephropathy (MN) and minimal change disease (MCD).

Methods

A retrospective analysis was performed at Changzheng Hospital from September 2022 to September 2024, and screened patients with rituximab-refractory MN or MCD. Participants were treated because they were refractory to rituximab and consented to receive infusions of obinutuzumab. Primary outcomes were defined as complete remission (CR, proteinuria <0.3 g/d) or partial remission (PR, proteinuria <3.5 g/d with a ≥50% reduction). Secondary outcome was immunological remission in patients with phospholipase A2 receptor (PLA2R)-related MN.

Results

Seven patients with MN and five with MCD were included in the cohort. Among patients with MN, six of seven (86%) achieved at least PR, of whom two patients reached CR with a median time to first remission (either PR or CR) of 8.0 months. Among patients with positive serum anti-PLA2R antibodies at baseline, all achieved an immunological response. No patients experienced a relapse during the follow-up period. Among patients with MCD, all patients achieved a CR with the median time of 1.0 months. Patients who were steroid-dependent or immunosuppressant-dependent were able to taper their medications in the short term without experiencing relapse. No treatment-related severe adverse events were reported.

Conclusions

Our study demonstrated that obinutuzumab represents a promising alternative therapeutic option for the management of rituximab-refractory MN and MCD.

Schlagwörter

Stichwörter der Autor:innen

membranous nephropathyminimal change diseasenephrotic syndromeobinutuzumabrituximab

Autor:innen und Institutionen

  • Department of Nephrology, Changzheng Hospital, Naval Medical University, Shanghai, China.
  • Department of Nephrology, The First Navy Hospital of Southern Theater Command, Zhanjiang, Guangdong, China.
  • Department of Cardiology, Changzheng Hospital, Naval Medical University, Shanghai, China.

Förderung

  • National Natural Science Foundation of China
  • Clinical Research Project of Shanghai Municipal Health Commission
  • Oriental Talent Plan Outstanding Program 2023, the Shanghai Municipal Key Clinical Specialty
  • Shanghai Shenkang Research Physician innovation and transformation ability training program
  • Scientific and technological innovation action plan of Shanghai medical innovation research special project
  • Science and Technology Research Plan of Zhanjiang

Zitieren

APA

Chen, Z., Xu, D., Wu, S., Liu, W., Wu, J., Yu, S., Dai, B., Mao, Z., & Gao, X. (2025). The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease. Clinical Kidney Journal, 18(3). https://doi.org/10.1093/ckj/sfaf039

Vancouver

Chen Z, Xu D, Wu S, Liu W, Wu J, Yu S, et al. The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease. Clinical Kidney Journal. 2025;18(3). doi:10.1093/ckj/sfaf039

BibTeX
@article{Chen2025,
  author = {Chen, Zewei and Xu, Dechao and Wu, Shuangcheng and Liu, Wenyu and Wu, Jianxiang and Yu, Shengqiang and Dai, Bing and Mao, Zhiguo and Gao, Xiang},
  title = {The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease},
  journal = {Clinical Kidney Journal},
  year = {2025},
  volume = {18},
  number = {3},
  doi = {10.1093/ckj/sfaf039}
}
Kostenlos starten →